Clinical trials for PIK3CA-related overgrowth syndrome
13 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT06997588EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)Novartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- RECRUITINGN/ANCT06840015Use of Airpod Pros as Assistive TechnologyThe University of Texas at Dallas · PI: Linda Thibodeau, Ph.D.
- RECRUITINGPhase 2NCT06789913A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA MutationRelay Therapeutics, Inc.
- RECRUITINGNCT06956248Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)National Cancer Centre, Singapore · PI: Daniel SW Tan, BSc(Hons), MBBS, MRCP, PhD
- RECRUITINGNCT06364579Patient Reported Outcomes (PROs) in Anal Cancer Patient Treated by Intensity Modulated Radiotherapy (IMRT).Fondazione Policlinico Universitario Agostino Gemelli IRCCS · PI: Stefania Manfrida
- RECRUITINGPHASE1, PHASE2NCT06975618Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)Haihe Biopharma Co., Ltd.
- RECRUITINGNCT05898932Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported OutcomesNorthwestern University · PI: James W. Griffith, PhD
- ACTIVE NOT RECRUITINGNCT05705947PROs Following Low-dose Irradiation for OsteoarthritisUniversity of North Carolina, Chapel Hill · PI: Theodore Yanagihara, MD, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT04980833Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)Novartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPhase 2NCT04589650Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth SpectrumNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGNCT04575402Digitally Captured Activity Data and PROs to Monitor Physical Function in Prostate Cancer PatientsCedars-Sinai Medical Center · PI: Gillian Gresham, PhD
- ACTIVE NOT RECRUITINGNCT05929001Lymphedema Specific PROs for Risk Assessment, Prevention and Early DetectionUniversity of Miami · PI: Eli Avisar, MD
- RECRUITINGPhase 2NCT04356209Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic " Patient Reported Outcome ") on Breast-related Quality of LifeInstitut du Cancer de Montpellier - Val d'Aurelle